Virion Therapeutics: VRON-0200 Shows Promising HBV Immunity in Phase 1b Trial

by

Archyde

Philadelphia, PA – In a significant development for the treatment of chronic hepatitis B virus (HBV) infection, Virion Therapeutics announced compelling data from its Phase 1b study evaluating VRON-0200. Presented…

You can read the full story here: Virion Therapeutics: VRON-0200 Shows Promising HBV Immunity in Phase 1b Trial.

Source link

Related posts:

  1. Fungal Peritoneal Dialysis-Associated Peritonitis as a Silent Threat: The Critical Role of Early Diagnosis and Catheter Removal – Cureus
  2. Beauvais Hospital Revolutionizes Cancer Care with State-of-the-Art Machinery
  3. New drug class may help alleviate IBS symptoms by targeting the central nervous system
  4. Radiotherapy: Shorter Treatments, Same Results

Leave a Comment